Total de visites
| Visites | |
|---|---|
| The ... | 61 |
Total de visites per mes
| de novembre 2023 | de desembre 2023 | de gener 2024 | de febrer 2024 | de març 2024 | d’abril 2024 | de maig 2024 | |
|---|---|---|---|---|---|---|---|
| The ... | 2 | 1 | 3 | 1 | 2 | 3 | 0 |
Total de descàrregues del fitxer
| Visites | |
|---|---|
| agamenon_seom_model_prediction_survival_patients_advanced_her2_positive_oesophagogastric_adenocarcinoma_receiving_first_line_trastuzumab_based_therapy_2023.pdf | 31 |
| agamenon_seom_model_prediction_survival_patients_advanced_her2_positive_oesophagogastric_adenocarcinoma_receiving_first_line_trastuzumab_based_therapy_2023_material_suplementari3.pdf | 14 |
| agamenon_seom_model_prediction_survival_patients_advanced_her2_positive_oesophagogastric_adenocarcinoma_receiving_first_line_trastuzumab_based_therapy_2023_material_suplementari1.pdf | 13 |
| agamenon_seom_model_prediction_survival_patients_advanced_her2_positive_oesophagogastric_adenocarcinoma_receiving_first_line_trastuzumab_based_therapy_2023_material_suplementari5.pdf | 12 |
| agamenon_seom_model_prediction_survival_patients_advanced_her2_positive_oesophagogastric_adenocarcinoma_receiving_first_line_trastuzumab_based_therapy_2023_material_suplementari4.pdf | 11 |
| agamenon_seom_model_prediction_survival_patients_advanced_her2_positive_oesophagogastric_adenocarcinoma_receiving_first_line_trastuzumab_based_therapy_2023_material_suplementari2.pdf | 10 |
Visites per país
| Visites | |
|---|---|
| Estats Units | 18 |
| Vietnam | 16 |
| Espanya | 11 |
| Alemanya | 7 |
| Irlanda | 5 |
| Finlàndia | 2 |
| Regne Unit | 1 |
| Suècia | 1 |
Visites per ciutat
| Visites | |
|---|---|
| Hanoi | 16 |
| Clonee | 5 |
| Barcelona | 4 |
| Ashburn | 3 |
| Boardman | 3 |
| The Dalles | 3 |
| Capellades | 1 |
| Frankfurt am Main | 1 |
| Helsinki | 1 |
| Lappeenranta | 1 |